iBio, Inc. (IBIO)
- Previous Close
1.7800 - Open
1.7960 - Bid 1.9100 x 1000
- Ask 1.9500 x 800
- Day's Range
1.7472 - 1.9300 - 52 Week Range
1.0200 - 24.4000 - Volume
154,045 - Avg. Volume
3,894,274 - Market Cap (intraday)
16.362M - Beta (5Y Monthly) -3.52
- PE Ratio (TTM)
-- - EPS (TTM)
-15.2500 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
www.ibioinc.comRecent News: IBIO
Performance Overview: IBIO
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IBIO
Valuation Measures
Market Cap
15.33M
Enterprise Value
29.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
115.48
Price/Book (mrq)
1.67
Enterprise Value/Revenue
580.19
Enterprise Value/EBITDA
-1.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.20%
Return on Equity (ttm)
-148.27%
Revenue (ttm)
50k
Net Income Avi to Common (ttm)
-20.77M
Diluted EPS (ttm)
-15.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
2.79M
Total Debt/Equity (mrq)
187.81%
Levered Free Cash Flow (ttm)
-99.12k